Skip to main content
Pfizer COVID-19 vaccine appointments are available to our patients.
Sign up for Connect today
to schedule your vaccination.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Joint Clinical Trials Office
Explore this Website
Home
About
Toggle About menu options
News
JCTO Contacts
Careers
Our Clinical Trial Locations
Partner with the JCTO
Toggle Partner with the JCTO menu options
JCTO Fees
Open Clinical Trials
Investigators
Patients
Toggle Patients menu options
What is a Clinical Trial?
Frequently Asked Questions
Clinical Trial Questions to Ask Your Healthcare Team
Clinical Trials: Common Terms to Know
Understanding Clinical Trials and How They Work
Understanding Clinical Trials - In Spanish | En Español
Weill Cornell Medicine
Care
Discover
Teach
Home
About
Open Clinical Trials
Investigators
Patients
Home
Clinical Trials
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date:
July 14, 2023
A Phase 1/2, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis
Study Status:
Open to Enrollment
Primary Investigator:
Date:
July 21, 2023
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 3, 2023
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 3, 2023
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 7, 2023
A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 9, 2023
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 9, 2023
A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 16, 2023
In Vivo Evaluation of Lymph Nodes Using Quantitative Ultrasound
Study Status:
Open to Enrollment
Primary Investigator:
Date:
August 29, 2023
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients with Select Advanced or Metastatic Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date:
September 1, 2023
« first
‹ previous
…
16
17
18
19
20
(current)
21
22
23
24
…
next ›
last »